- About Us
- Media Release
- Our Clients
- Media Mentions
- Subscription Model
- Contact Us
The Latin America, Middle East and Africa Inhaled Nitric Oxide Market would witness market growth of 8.5% CAGR during the forecast period (2020-2026). Inhaled Nitric Oxide acts as a pulmonary vasodilator that helps in controlling vascular muscle tone.
The field of Nitric Oxide has evolved during the last century, to embed various fields of bio-medical research due to its acknowledgment as a prime endothelial-derived vasodilator molecule. Presently, Nitric Oxide acts as an important signalling molecule all over the body.
The inhaled nitric oxide market is expected to increase over the forecast period due to the increasing prevalence of respiratory diseases, the increasing number of breathing problems in infants, and the initiatives by the FDA to motivate clinical use of inhaled nitric oxide. Additionally, technological improvements in inhaled nitric oxide and the latest product introduced by the companies operating in the market are anticipated to offer lucrative opportunities over the forecast period.
Nitric oxide, at room temperature, is a colorless and odorless gas that is soluble in water. Although there are many advantages of nitric oxide, but the potential therapeutic value of inhaled nitric oxide is uncertain in adults & authorized indications are limited to pediatric practice. Moreover, there is some recent modification in the marketing of the inhaled nitric oxide, has added to the cost of nitric oxide treatment. Inhaled nitric oxide is a therapeutic therapy with broad capabilities for pediatric clinical usage.
Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Neonatal Respiratory Treatment market dominated the South Africa Inhaled Nitric Oxide Market by Application in 2019, thereby, achieving a market value of $5.8 Million by 2026. The Chronic Obstructive Pulmonary Disease (COPD) market is showcasing a CAGR of 9.6% during (2020 - 2026).
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.